Episalvan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

birch bark extract
MedicineHumanWithdrawn

Croatian is available via eTranslation, the European Commission's machine translation service.

Translate to Croatian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 7 June 2022, the European Commission withdrew the marketing authorisation for Episalvan (birch bark extract) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amryt GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Episalvan was granted marketing authorisation in the EU on 14 January 2016 for the treatment of partial thickness wounds in adults. 

The European Public Assessment Report (EPAR) for Episalvan is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (296.74 KB - PDF)

Prikaži

español (ES) (245.78 KB - PDF)

Prikaži

čeština (CS) (287.15 KB - PDF)

Prikaži

dansk (DA) (244.24 KB - PDF)

Prikaži

Deutsch (DE) (250.92 KB - PDF)

Prikaži

eesti (ET) (242.95 KB - PDF)

Prikaži

ελληνικά (EL) (317.24 KB - PDF)

Prikaži

français (FR) (250.22 KB - PDF)

Prikaži

hrvatski (HR) (267.8 KB - PDF)

Prikaži

italiano (IT) (244.82 KB - PDF)

Prikaži

latviešu (LV) (285 KB - PDF)

Prikaži

lietuvių (LT) (270.73 KB - PDF)

Prikaži

magyar (HU) (291.39 KB - PDF)

Prikaži

Malti (MT) (289.33 KB - PDF)

Prikaži

Nederlands (NL) (248.9 KB - PDF)

Prikaži

polski (PL) (287.6 KB - PDF)

Prikaži

português (PT) (246.11 KB - PDF)

Prikaži

română (RO) (269.5 KB - PDF)

Prikaži

slovenčina (SK) (287.29 KB - PDF)

Prikaži

slovenščina (SL) (279.06 KB - PDF)

Prikaži

suomi (FI) (244.39 KB - PDF)

Prikaži

svenska (SV) (244.65 KB - PDF)

Prikaži

Product information

български (BG) (808.66 KB - PDF)

Prikaži

español (ES) (404.89 KB - PDF)

Prikaži

čeština (CS) (640.06 KB - PDF)

Prikaži

dansk (DA) (413.47 KB - PDF)

Prikaži

Deutsch (DE) (432.51 KB - PDF)

Prikaži

eesti (ET) (398.81 KB - PDF)

Prikaži

ελληνικά (EL) (843.43 KB - PDF)

Prikaži

français (FR) (426.81 KB - PDF)

Prikaži

hrvatski (HR) (494.83 KB - PDF)

Prikaži

italiano (IT) (413.48 KB - PDF)

Prikaži

latviešu (LV) (676.12 KB - PDF)

Prikaži

lietuvių (LT) (503.12 KB - PDF)

Prikaži

magyar (HU) (653.64 KB - PDF)

Prikaži

Malti (MT) (668.13 KB - PDF)

Prikaži

Nederlands (NL) (420.11 KB - PDF)

Prikaži

polski (PL) (672.77 KB - PDF)

Prikaži

português (PT) (413.49 KB - PDF)

Prikaži

română (RO) (513.12 KB - PDF)

Prikaži

slovenčina (SK) (659.65 KB - PDF)

Prikaži

slovenščina (SL) (633.51 KB - PDF)

Prikaži

suomi (FI) (464.57 KB - PDF)

Prikaži

svenska (SV) (412.87 KB - PDF)

Prikaži

Íslenska (IS) (412.08 KB - PDF)

Prikaži

norsk (NO) (409.62 KB - PDF)

Prikaži
07/06/2022
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (213.15 KB - PDF)

Prikaži

español (ES) (179.64 KB - PDF)

Prikaži

čeština (CS) (206.85 KB - PDF)

Prikaži

dansk (DA) (178.94 KB - PDF)

Prikaži

Deutsch (DE) (179.35 KB - PDF)

Prikaži

eesti (ET) (179.37 KB - PDF)

Prikaži

ελληνικά (EL) (214.3 KB - PDF)

Prikaži

français (FR) (178.46 KB - PDF)

Prikaži

hrvatski (HR) (192.58 KB - PDF)

Prikaži

italiano (IT) (180 KB - PDF)

Prikaži

latviešu (LV) (238.07 KB - PDF)

Prikaži

lietuvių (LT) (197.73 KB - PDF)

Prikaži

magyar (HU) (204.56 KB - PDF)

Prikaži

Malti (MT) (207.5 KB - PDF)

Prikaži

Nederlands (NL) (179.14 KB - PDF)

Prikaži

polski (PL) (206.18 KB - PDF)

Prikaži

português (PT) (179.38 KB - PDF)

Prikaži

română (RO) (196.46 KB - PDF)

Prikaži

slovenčina (SK) (206.29 KB - PDF)

Prikaži

slovenščina (SL) (200.6 KB - PDF)

Prikaži

suomi (FI) (180.06 KB - PDF)

Prikaži

svenska (SV) (180.74 KB - PDF)

Prikaži

Íslenska (IS) (184.82 KB - PDF)

Prikaži

norsk (NO) (184.87 KB - PDF)

Prikaži

Product details

Name of medicine
Episalvan
Active substance
Betulae cortex
International non-proprietary name (INN) or common name
birch bark extract
Therapeutic area (MeSH)
  • Wounds and Injuries
  • Wound Healing
Anatomical therapeutic chemical (ATC) code
D03AX13

Pharmacotherapeutic group

Preparations for treatment of wounds and ulcers

Therapeutic indication

Treatment of partial thickness wounds in adults. See sections 4.4 and 5.1 in Product Information with respect to type of wounds studied.

Authorisation details

EMA product number
EMEA/H/C/003938
Marketing authorisation holder
Amryt AG

Streiflingsweg 11
75223 Niefern-Oschelbronn
Germany

Opinion adopted
19/11/2015
Marketing authorisation issued
14/01/2016
Withdrawal of marketing authorisation
07/06/2022
Revision
7

Assessment history

This page was last updated on

Share this page